louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01826409: Hypoglycemic Effects of Fermented Red Ginseng in Subject With Impaired Fasting Glucose or Type 2 Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Impaired Glucose or Type 2 Diabetes
Lead sponsor: Chonbuk National University Hospital
Sponsor class: OTHER
First posted: 2013-04-08
Enrollment: 42
Sex: ALL
Minimum age (years): 20
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study was conducted to investigate the effects of daily supplementation of fermented red ginseng (FRG) on glycemic status in subjects with impaired fasting glucose (IFG) or type 2 diabetes.

Detailed description: This study was a 4 weeks, randomized, double-blind, placebo-controlled trial. Forty-two subjects with IFG or type 2 diabetes were randomly allocated to 2 groups to consume placebo or FRG three times per day for 4 weeks. Fasting and postprandial glucose profiles during meal tolerance test were assessed before and after the intervention.

Eligibility criteria: Inclusion Criteria:

* Age 20-75 years with fasting glucose 100\~140 mg/dL at least two of the following

Exclusion Criteria:

* Lipid metabolic disorder
* Acute or chronic inflammatory disease
* Taking medication of corticosteroid within 4 weeks of the study
* Cardiovascular disease (arrhythmia, heart failure, myocardial infarction or patient with pacemaker)
* Allergic or hypersensitive to any of the ingredients in the test products
* Participation in other clinical trials within 2 months
* Abnormal hepatic liver function or renal disease (acute/chronic renal failure or nephrotic syndrome)
* Taking medication of lipid phosphates within 3 months of the study etc,

Primary outcomes:
measure: Glucose profiles during meal tolerance test
timeFrame: 4 weeks
Secondary outcomes:
measure: Change in lipid profiles
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Jeonju
country: Korea, Republic of
facility: Clincial Trial Center for Functional Foods
state: Jeollabok-do
Study officials:
affiliation: Chonbuk National University Hospital
name: Tae Sun Park, MD., PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Oh MR, Park SH, Kim SY, Back HI, Kim MG, Jeon JY, Ha KC, Na WT, Cha YS, Park BH, Park TS, Chae SW. Postprandial glucose-lowering effects of fermented red ginseng in subjects with impaired fasting glucose or type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. BMC Complement Altern Med. 2014 Jul 11;14:237. doi: 10.1186/1472-6882-14-237.
Clinical trial NCT02016209: Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Lung Cancer
Official title: Phase II Study of Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin/Cisplatin in Stage Ⅱ B and IIIA Non-small Cell Lung Cancer Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Non Small Cell Lung Cancer
Lead sponsor: Zhejiang University
Sponsor class: OTHER
First posted: 2013-12-19
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: platinum-based albumin-bound paclitaxel regimen in advanced non-small cell lung cancer (NSCLC) especially in lung squamous cell carcinoma has a better tumor response rate and safety than solvent-based paclitaxel.However, the safety and efficacy is uncertain in neoadjuvant therapy.

Detailed description: The main purpose of this study is to observe the safety and efficacy of platinum-based albumin-bound paclitaxel regimen in the treatment of non-small cell lung cancer (NSCLC) of stage Ⅱ B and IIIA .

Eligibility criteria: Inclusion Criteria:

1.Histological or cytological diagnosis of NSCLC of Stage Ⅱ B and IIIA .

2.18 years or older 3.Performance Status 0 to 2; 4.Appraisable disease; 5.patients can tolerant chemotherapy; 6.Total bilirubin 1.5 x upper limit of normal (ULN); 7.Creatinine clearance 60ml/min (calculated according to Cockcroft-gault formula).

Exclusion Criteria:

1.Any systemic anticancer treatment for NSCLC；2.Local radiotherapy for NSCLC；3.In this study within five years prior to the start of treatment with other than NSCLC patients with other cancers.4.Any instability in systemic disease; 5.Allergic to paclitaxel or Platinum;6.Pregnant or lactating women;7.Other researchers believe that does not fit into the group

Primary outcomes:
measure: Tumor response rate and Number of Adverse Events
timeFrame: From date of randomization until the date of progression, assessed up to 2 months
Secondary outcomes:
measure: disease free survival
timeFrame: From date of surgery until the date of first documented progression, assessed up to 36 months
Other outcomes:
measure: dynamic circulating tumor cell changes during treatment
timeFrame: baseline, 3 weeks and up to progression disease
Locations:
city: Hangzhou
country: China
facility: The first affiliated hospital, Zhejiang University
state: Zhejiang
Study officials:
affiliation: The First Affiliated Hospital, Zhejiang University
name: Qiong Zhao, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02481609: NAC Trial for Anosmia
Official title: Pilot Study of Topical Intranasal N-acetyl Cysteine Administration for the Treatment of Anosmia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Anosmia
Keywords: Loss of Smell
Olfaction
Hyposmia
Lead sponsor: University of Miami
Sponsor class: OTHER
First posted: 2015-06-25
Enrollment: 29
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this research study is to evaluate the use of NAC in the treatment of anosmia (a loss of the sense of smell). This drug is already approved by the Food and Drug Administration (FDA) for oral or pulmonary (lung) inhaled use for other medical conditions. However, there is research evidence that the medication may promote nerve recovery (help nerves work better after they are damaged). Since anosmia involves nerve problems, we believe the nasal spray may help treat anosmia. The medication has been in use for many years for other conditions, without safety problems.


Eligibility criteria: Inclusion Criteria:

* adults at least 18 years of age with documented microsmia or anosmia by University of Pennsylvania Smell Identification Test.
* patients must have no evidence of active sinonasal disease by nasal endoscopy or CT or MRI
* negative CT or MRI

Exclusion Criteria:

* adults unable to consent
* individuals who are not yet adults (infants, children, teenagers)
* pregnant women, prisoners, employees or subordinates,
* patients with known sensitivity to NAC or severe asthma
* patients with sinus or central disease on CT or MRI imaging.

Primary outcomes:
measure: Change in the Smell Identification Test score
timeFrame: Baseline and three months after completion of treatment
Secondary outcomes:
measure: Change in Sino-Nasal Outcome Test (SNOT-20) score
timeFrame: Baseline and three months after completion of treatment
Other outcomes:
Locations:
city: Miami
country: United States
facility: University of Miami, Miller School of Medicine, Clinical Research Building
state: Florida
Study officials:
affiliation: University of Miami
name: Bradley J Goldstein, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00237809: D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia
Official title: D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Schizophrenia
Schizoaffective Disorder
Lead sponsor: Yale University
Sponsor class: OTHER
Collaborators: name: National Alliance for Research on Schizophrenia and Depression
name: Donaghue Medical Research Foundation
First posted: 2005-10-12
Enrollment: 104
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is based on the hypothesis that by increasing N-methyl-D-aspartic acid (NMDA) receptor function in the brain and thereby increasing the capacity of the brain to both form new connections and strengthen existing connections, schizophrenic patients may derive both greater and sustained benefit from cognitive retraining.

Detailed description: Patients with schizophrenia or schizoaffective disorder who are currently receiving antipsychotic medication will be randomly assigned in a double-blind manner to receive either D-serine (30 mg/kg) or placebo in addition to cognitive rehabilitation or a non-interactive placebo for 12 weeks.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of schizophrenia or schizoaffective disorder

Exclusion

* Pregnant or lactating

Primary outcomes:
measure: Wisconsin Card Sorting Test (WCST)
timeFrame: 12 weeks
measure: Hopkins Verbal Learning Test
timeFrame: 12 weeks
measure: Spatial Span- Total Score
timeFrame: 12 weeks
measure: Positive and Negative Syndrome Scale (PANSS)
timeFrame: 12 weeks
Secondary outcomes:
measure: Heinrichs-Carpenter Quality of Life Scale
timeFrame: 12 weeks
measure: Simpson-Angus Neurological Rating Scale
timeFrame: 12 weeks
measure: UCSD Performance-Based Skills Assessment (UPSA)
timeFrame: 12 weeks
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Connecticut Mental Health Center
state: Connecticut
city: West Haven
country: United States
facility: VA Connecticut Healthcare System
state: Connecticut
Study officials:
affiliation: Yale University
name: Deepak C D'Souza, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JT. D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry. 1999 Nov;156(11):1822-5. doi: 10.1176/ajp.156.11.1822.
citation: Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 1998 Dec 1;44(11):1081-9. doi: 10.1016/s0006-3223(98)00279-0.
citation: Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G, Catinari S, Ermilov M. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry. 2005 Mar 15;57(6):577-85. doi: 10.1016/j.biopsych.2004.12.037.
Clinical trial NCT05894109: Efficacy of Zinc Supplementation on Botox Treated Forehead Rhytids
Official title: Efficacy of Zinc Supplementation on Botox Treated Forehead Rhytids
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Adjuvant Zinc May Increase the Efficacy of Botulinum Toxin
Zinc Supplementation for Botulinum Toxin Treatment of the Forehead
Glabellar Frown Lines
Botulinum Toxin, Cosmetic
Adjuvant Oral Zinc and Botulinum Toxin
Lead sponsor: University of New Mexico
Sponsor class: OTHER
Collaborators: name: AbbVie
First posted: 2023-06-08
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Repeated Measures ANOVA (Continuous Data) McNemar Test (Categorical Data)
Primary purpose: TREATMENT

Brief summary: The current literature suggests that zinc supplementation may increase the duration of botulinum toxin; however, each study had their limitations. Further, no one has studied the effect of zinc supplementation for botulinum toxin treatment of the forehead. The purpose of this study is to evaluate the effect of zinc supplementation on frontalis muscle denervation by objectively assessing the degree of forehead rhytids and movement of the eyebrows.


Eligibility criteria: Inclusion Criteria:

Any patient older than 18 years old who desires botulinum toxin injection to decrease forehead rhytids

Exclusion Criteria:

* Allergy to any components of zinc citrate or botulinum toxin
* inflammation or infection at site of injection
* patients using anticholineresterase or other agents interfering with neuromuscular transmission
* patients with any medical condition that can affect frontalis function (Bell's palsy, Möbius syndrome, Hemifacial microsomia, CHARGE syndrome, stroke, etc)
* patients with any prior trauma that could have potentially injured the frontalis muscle
* patients dependent on intact facial movements and expressions for their livelihood (actors, singers, musicians, etc)

Primary outcomes:
measure: Duration of botulinum toxin on eyebrow excursion
timeFrame: 1 year
measure: Duration of botulinum toxin effect on forehead rhytids
timeFrame: 1 year
Secondary outcomes:
measure: Side effects of zinc administration
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
References:
citation: Koshy JC, Sharabi SE, Feldman EM, Hollier LH Jr, Patrinely JR, Soparkar CN. Effect of dietary zinc and phytase supplementation on botulinum toxin treatments. J Drugs Dermatol. 2012 Apr;11(4):507-12.
citation: Shemais N, Elarab AE, ElNahass H. The effect of botulinum toxin A in patients with excessive gingival display with and without zinc supplementation: randomized clinical trial. Clin Oral Investig. 2021 Nov;25(11):6403-6417. doi: 10.1007/s00784-021-03944-2. Epub 2021 May 5.
Clinical trial NCT03015909: Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj.
Official title: A Multi-center, Open, Single-arm, Switch-over, Prospective, Phase IV Study to Assess the Ease of Use, Preference, and Safety After 8 Weeks Subcutaneous Administration of EutropinPen Inj. in Patients Pretreated With Recombinant Human Growth Hormone by Reusable Device
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Short Stature, Idiopathic
Infant, Small for Gestational Age
Growth Hormone Deficiency
Chronic Renal Failure
Turner Syndrome
Lead sponsor: LG Life Sciences
Sponsor class: INDUSTRY
First posted: 2017-01-10
Enrollment: 116
Sex: ALL
Minimum age (years): 4
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the ease of use, preference, and safety after 8 weeks subcutaneous administration of EutropinPen Inj. in patients pretreated with recombinant human growth hormone by reusable device.


Eligibility criteria: Inclusion Criteria:

* Subjects who has been using reusable device growth hormone injection in recent 3 months at least for 6 weeks
* Subjects who meets the indication of EutropinPen inj.

Exclusion Criteria:

* Subjects who has diseases below on screening visit

  * Diabetes
  * Malignant tumor
  * Epiphyseal closure
  * Chronic kidney disease (recieved kidney transplantation)
  * Acute respitory failure

Primary outcomes:
measure: Ease of use for EutropinPen Inj. against previous reusable device assessed by a questionnaire.
timeFrame: Day 57
measure: Preference for EutropinPen Inj. against previous reusable device assessed by a questionnaire.
timeFrame: Day 57
Secondary outcomes:
measure: Benefits of EutropinPen inj. assessed by a questionnaire
timeFrame: Day 57
measure: Fear assessed by a questionnaire
timeFrame: Screening, Day 57
measure: Ease of use for EutropinPen Inj. at each injection step assessed by a questionnaire
timeFrame: Screening, Day 57
measure: Treatment compliance of EutropinPen Inj. (%)
timeFrame: Day 57
Other outcomes:
Locations:
city: Suwon
country: Korea, Republic of
facility: Ajou university hospital
state: Gyeong-gi
Study officials:
References:
citation: Lee JE, Kim SY, Yoo JH, Hwang IT, Lim JS, Yi KH, Rhie YJ, Lee GM, Nam HK, Chae HW, Kim EY, Cheon CK, Lee J, Shim YS, Lee Y, Kim EY, Hwang JS. Ease of Use, Preference, and Safety of the Recombinant Human Growth Hormone Disposable Pen Compared with the Reusable Device: A Multicenter, Single-Arm, Open-Label, Switch-Over, Prospective, Phase IV Trial. Patient Prefer Adherence. 2019 Dec 20;13:2195-2205. doi: 10.2147/PPA.S229536. eCollection 2019.
Clinical trial NCT00217009: Study to Compare Different Light Therapies (Narrowband Ultraviolet B vs PUVA) for Hand and Foot Skin Diseases.
Official title: A Randomized Controlled Trial of Narrowband Ultraviolet B vs Topical Psoralen Plus Ultraviolet A Photochemotherapy for Hand and Foot Dermatoses
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: EARLY_PHASE1
Conditions: Dermatitis
Psoriasis
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2005-09-22
Enrollment: 3
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Hand and foot skin diseases, such as dermatitis and psoriasis, that do not respond to topical creams can be treated with ultraviolet light therapy. Topical psoralen plus ultraviolet A (PUVA) is commonly used to treat these conditions, but requires additional time for the hands and feet to soak in psoralens before the light treatment. Newer narrowband ultraviolet B (NBUVB) units have become available which allow for light treatment without soaking first. The purpose of this study is to determine if NBUVB is as effective as PUVA for hand and foot skin diseases.


Eligibility criteria: Inclusion Criteria:

Bilateral hand or foot skin disease (dermatitis, psoriasis, etc.) with symmetric distribution and severity.

Exclusion Criteria:

Age \<18 years Pregnancy Liver disease Kidney disease History of skin cancer Phototherapy or systemic therapy for the skin condition in the preceding 3 months

Primary outcomes:
measure: Number of treatments required to reach clearance
timeFrame: Baseline to 15 months
Secondary outcomes:
measure: Change in symptom score (erythema, scaling/hyperkeratosis, papular/vesicular eruption, and fissures)
timeFrame: Baseline to 15 months
measure: Change in global score
timeFrame: Baseline to 15 months
measure: Number of patients reaching clearance
timeFrame: Baseline to 15 months
measure: Adverse effects
timeFrame: Baseline to 15 months
measure: Number of days in remission
timeFrame: Baseline to 15 months
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Mark D. Davis, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02332109: ODM 5 in the Treatment of Corneal Edematous Fuchs' Endothelial Dystrophy
Official title: ODM 5 in the Treatment of Corneal Edematous Fuchs' Endothelial Dystrophy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Fuchs' Endothelial Dystrophy
Corneal Edema
Keywords: Fuchs endothelial dystrophy
oedema
sodium chloride
hyaluronan
sodium hyaluronate
Lead sponsor: TRB Chemedica AG
Sponsor class: INDUSTRY
First posted: 2015-01-06
Enrollment: 29
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with a Fuchs endothelial dystrophy-induced corneal edema and an ODM 5 therapy recommendation.

Brief summary: Clinical observation to confirm the clinical safety and efficacy of ODM 5 in the treatment of corneal edema caused by Fuchs' endothelial dystrophy.

Detailed description: Patients with a Fuchs' endothelial dystrophy-induced corneal edema and an ODM 5 therapy recommendation prior to their inclusion will be observed in normal practice setting in this post-market clinical follow-up study. In this indication, the use of ODM 5 should extract the fluid excess in the cornea away by an osmotic effect, enabling the cornea to temporarily regain a normal state of hydration. As a consequence, the patient's visual acuity, contrast perception, corneal thickness and ocular complaints/symptoms should improve. The hyaluronan in ODM 5 helps to protect and heal the cornea in case of irritation and thus, enables the cornea to regain a normal state of hydration and participates in improving the quality of vision.

Eligibility criteria: Inclusion Criteria:

* Presence of corneal oedema caused by Fuchs' endothelial dystrophy
* Existing ODM 5 recommendation prior to inclusion

Exclusion Criteria:

* Contact lens wear
* Hypersensitivity to one of the ODM 5 components
* Appointment for eye surgery within 8 weeks after date of inclusion

Primary outcomes:
measure: Visual acuity (both eyes)
timeFrame: Day 56
Secondary outcomes:
measure: Corneal thickness
timeFrame: Day 0, day 28 and day 56
measure: Visual acuity (both eyes)
timeFrame: Day 0 and day 28
measure: Contrast perception (Measurement of contrast values (both eyes))
timeFrame: Day 0, day 28 and day 56
measure: Subjective ocular complaints and symptoms (11-point Likert scale)
timeFrame: Day 0, day 28 and day 56
measure: Safety parameter (Adverse events)
timeFrame: Day 0, day 28 and day 56
Other outcomes:
Locations:
city: Düsseldorf
country: Germany
facility: Universitätsklinikum Düsseldorf, Augenklinik
city: Heidelberg
country: Germany
facility: Praxis Dr. Thomas Kaercher
city: Magdeburg
country: Germany
facility: Universitätsklinikum Magdeburg A.ö.R., Universitätsaugenklinik
city: München
country: Germany
facility: Augenklinik der Ludwig-Maximilians-Universität (LMU), Klinikum der Universität München
Study officials:
References:
Clinical trial NCT02059109: Evaluation of a Training Model for the Proficient Use of the Belmont Rapid Infuser
Official title: Evaluation of a Training Model for the Proficient Use of the Belmont Rapid Infuser
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Use of the Belmont Rapid Infuser
Keywords: Belmont
Rapid
Infuser
proficiency
proficient
training
Lead sponsor: Children's Hospital Medical Center, Cincinnati
Sponsor class: OTHER
First posted: 2014-02-11
Enrollment: 56
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: The Belmont Rapid Infuser is a device currently approved to replace larger volumes of necessary fluids such as blood in a fast and safe manner. The purpose of the study is to evaluate proficiency and the retention of knowledge of how to use the device based on current methods of training compared to revised training methods.

Hypotheses:

1. The use of the traditional method of training is not effective, predicting less then half of staff will pass on the first attempt.
2. Restructured test with hands-on training as opposed to oral presentation only with a written test will result in a pass rate of \> 80%.
3. Staff members who work in pairs will perform better than working alone when setting up the Belmont Rapid Infuser (BRI).
4. Retention at 3 months will be higher with the restructured training method than with the traditional training method.

Detailed description: Participants will be recruited to complete a test after undergoing either the traditional or the restructured training method. This training will be completed on one day and takes about 1 hour.

All participants who pass via either method of training are evaluated again to test retention 3-4 months later .

Eligibility criteria: Inclusion Criteria:

* Participants will be recruited from the faculty, Certified Registered Nurse Anesthetists, and fellows from the Department of Anesthesia at Cincinnati Children's Hospital Medical Center.
* They may have had educational exposure or use of the Belmont Rapid Infuser without independent assembly.

Exclusion Criteria:

* None

Primary outcomes:
measure: Proficiency
timeFrame: Measured after the training session (approximately 1 hour).
Secondary outcomes:
measure: Retention of proficiency
timeFrame: 3 -4 months after delivery of the effective teaching model.
Other outcomes:
Locations:
city: Cincinnati
country: United States
facility: Cincinnati Children's Medical Center
state: Ohio
Study officials:
References: